syndrome [1] , necrotizing and crescenting glomerulonephritis [3, 5] , minimal lesion glomerulopathy [2] , extracapillary glomerulonephritis with IgA deposits or active follicular necrosis against a background of glomerular sclerosis [4] .
It is noteworthy that, as with this Crohn's disease case, favourable outcomes have been reported in all other rheumatoid arthritis cases. After adalimumab discontinuation and glucocorticoid [4] and/or immunosuppressive therapy [3, 5] , renal function recovered within a few weeks. Of interest, in one case proteinuria relapsed after adalimumab rechallenge [2] .
In this case, the relative contributions of adalimumab and of the underlying Crohn's disease to the development of proteinuria cannot be exactly determined. However, it is questionable whether in this particular patient adalimumab induction scheme was the only factor able to induce proteinuria. We believe that the complete reversibility of proteinuria after adalimumab discontinuation points towards adalimumab as a triggering factor to a strongly predisposed for a renal dysfunction individual.
As there have been some concerns regarding safety issues during administration of anti-TNF-α agents, it is of importance to understand the mechanism(s) of their interference in the normal kidney function. By this way, we may able to properly screen and possibly identify high-risk groups before initiation of anti-TNF-α therapies. For the moment, careful patient selection for biological agents as well as regular follow-up can promptly diagnose and completely reverse rare or unexpected episodes. There has been an ongoing discussion whether pruritus in chronic kidney disease is brought about by the common disturbance of calcium/phosphate homeostasis [2] .
Recently it has been proposed that a vicious circle of metabolic derangements (malnourishment, inflammation, arteriosclerosis) may explain the exaggerated morbidity and mortality in a subset of haemodialysis patients [3] . Inflammation might be the most deleterious factor in this respect which, besides other factors, is related to the occurrence of CKD-rP and down-regulation of fetuin-A, an important calcium-binding circulating protein favouring tissuecalcifications in these patients [4] .
Thus, we were interested in whether patients with CKDrP display lower levels of serum fetuin-A.
Ten patients in a hospital-based haemodialysis centre complaining about CKD-rP were compared to another 12 patients who did not report to have suffered from CKDrP at least 6 months prior to the interview. Patients with CKD-rP were asked to score the intensity of current pruritus using a visual analogue scale (VAS) ranging from 0 to 10. In both groups, 10 ml of blood was taken immediately after puncture of the arterio-venous fistula, and fetuin-A, 25-hydroxyvitamin D 3 (25[OH]D 3 ), total protein, albumin, calcium (corrected for serum albumin), phosphate, and high-sensitivity CRP (hsCRP) were measured.
Independent t-tests (continuous variables) and a χ 2 -test (gender) evaluated whether there were significant (P < 0.05) differences between patients with and without CKD-rP.
The mean pruritus intensity of patients with CKD-rP was 5.9 ± 1.9. After identifying one univariate outlier (hsCKP = 35.6) in the group of patients without CKDrP, CRP was significantly higher in patients with CKD-rP. We failed, however, to find significant differences in serumcalcium, phosphate, fetuin A and 25-OH-Vitamin D3 between the two groups (Table 1) . Additionally, there was no relationship between the intensity of CKD-rP and the metabolic factors measured (including CRP) in patients suffering from pruritus.
Although our study approach has methodological limitations (small number of patients, no matched pairs) the results suggest that neither calcium-binding protein fetuin-A levels nor 25(OH)D 3 values were noticeably different in patients with CKD-rP compared to patients without CKD-rP. On the other hand, the marker for inflammation, CRP, was found to be significantly higher in patients with CKD-rP as shown before [5] . We hence believe that other inflammation-driven processes need to be studied in the future in order to understand the pathomechanisms of CKD-rP.
